121 related articles for article (PubMed ID: 36728981)
21. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study.
Ding J; Leng Z; Gu H; Jing X; Song Y
Front Oncol; 2023; 13():1153131. PubMed ID: 37361601
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
Yu L; Xu J; Qiao R; Han B; Zhong H; Zhong R
Cancer Med; 2023 Mar; 12(5):5372-5383. PubMed ID: 36250532
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Anlotinib for Elderly Patients with Previously Treated Extensive-Stage SCLC and the Prognostic Significance of Common Adverse Reactions.
Song PF; Xu N; Li Q
Cancer Manag Res; 2020; 12():11133-11143. PubMed ID: 33173346
[TBL] [Abstract][Full Text] [Related]
24. Anlotinib-containing regimen for advanced small-cell lung cancer: A protocol of meta-analysis.
Yu G; Cai Q; Xu X; Shen Y; Xu K
PLoS One; 2021; 16(3):e0247494. PubMed ID: 33705427
[TBL] [Abstract][Full Text] [Related]
25. A Prospective Study of Apatinib in Patients with Extensive-Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy.
Liu Y; Hu X; Jiang J; Yang L; Zhou S; Liu P; Li J; Wang Y; Hao X; Shi Y
Oncologist; 2020 May; 25(5):e833-e842. PubMed ID: 32250517
[TBL] [Abstract][Full Text] [Related]
26. Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202).
Shi J; Cheng Y; Wang Q; Li K; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Front Med; 2022 Oct; 16(5):766-772. PubMed ID: 35844026
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of anlotinib in patients with small-cell lung cancer and pleural effusion: Subgroup analysis from a randomized, multicenter, phase II study.
Liu Y; Cheng Y; Wang Q; Li K; Shi J; Wu L; Han B; Chen G; He J; Wang J; Qin H; Li X
Thorac Cancer; 2021 Nov; 12(22):3039-3045. PubMed ID: 34596367
[TBL] [Abstract][Full Text] [Related]
28. Apatinib as maintenance therapy in extensive-stage small-cell lung cancer: results from a single-center retrospective study.
Yan X; Wang Q; Wang H; Li P; Zhang G; Zhang M; Zheng X; Yang J; Zhang X; Ma Z
J Cancer Res Clin Oncol; 2019 Jan; 145(1):235-240. PubMed ID: 30293117
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of anlotinib for subsequent line treatment of small cell lung cancer: a systematic review and meta-analysis.
Xu H; Cao D; Jie F; He A; Ge W
Tumori; 2023 Apr; 109(2):203-214. PubMed ID: 35509221
[TBL] [Abstract][Full Text] [Related]
30. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial.
Deng P; Hu C; Chen C; Cao L; Gu Q; An J; Qin L; Li M; He B; Jiang J; Yang H
Cancer Med; 2022 Oct; 11(19):3563-3571. PubMed ID: 35526266
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
Spigel DR; Greco FA; Rubin MS; Shipley D; Thompson DS; Lubiner ET; Eakle JF; Quinn R; Burris HA; Hainsworth JD
Lung Cancer; 2012 Aug; 77(2):359-64. PubMed ID: 22560921
[TBL] [Abstract][Full Text] [Related]
32. The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: a case report.
Deng W; Chen J; Deng XY
Front Immunol; 2024; 15():1333850. PubMed ID: 38487532
[TBL] [Abstract][Full Text] [Related]
33. A phase II study of anlotinib in 45 patients with relapsed small cell lung cancer.
Wu D; Nie J; Hu W; Dai L; Zhang J; Chen X; Ma X; Tian G; Han J; Han S; Long J; Wang Y; Zhang Z; Fang J
Int J Cancer; 2020 Dec; 147(12):3453-3460. PubMed ID: 32557583
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
Jiang HT; Li W; Zhang B; Gong Q; Qie HL
Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
[TBL] [Abstract][Full Text] [Related]
35. Anlotinib combined with durvalumab in a patient with recurrent multifocal brain metastases of small cell lung cancer after definitive concurrent chemoradiotherapy and palliative radiotherapy of the lung and brain: a case report.
Wu Y; Zhang T; Liu Y; Wang J; Bi N
Ann Palliat Med; 2021 Feb; 10(2):2379-2386. PubMed ID: 33725780
[TBL] [Abstract][Full Text] [Related]
36. Successful Treatment of a Patient With Multiple-Line Relapsed Extensive-Stage Small-Cell Lung Cancer Receiving Penpulimab Combined With Anlotinib: A Case Report.
Zhang Z; Li Y; Dong Y; Li J; Zhang B; Zhang C; Cui X
Front Oncol; 2022; 12():846597. PubMed ID: 35321433
[TBL] [Abstract][Full Text] [Related]
37. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.
Cheng Y; Wang Q; Li K; Shi J; Liu Y; Wu L; Han B; Chen G; He J; Wang J; Lou D; Yu H; Wang S; Qin H; Li X
Br J Cancer; 2021 Aug; 125(3):366-371. PubMed ID: 34006926
[TBL] [Abstract][Full Text] [Related]
38. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
39. Anlotinib Combined with S-1 in the Third-Line Treatment of Stage IV Non-Small Cell Lung Cancer: Study Protocol for Phase II Clinical Trial.
Yang X; Xiang M; Geng L; Wen Y; Du X
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3849-3853. PubMed ID: 31870132
[TBL] [Abstract][Full Text] [Related]
40. [Clinical study of antinib combined with radiotherapy in the treatment of third-line extensive small cell lung cancer].
Zong YF; Tan Y; Baerxiaguli Z; Wang HF
Zhonghua Zhong Liu Za Zhi; 2023 Oct; 45(10):892-897. PubMed ID: 37875425
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]